Sign In
Buy VECT
$16.85
+0 (+0%)
At Close: Oct 06, 2023
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
07:19am, Thursday, 24'th Jun 2021
Phase 2 trial expected to begin in the first quarter of 2022 Phase 2 trial expected to begin in the first quarter of 2022
Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IF CIC patients represent over half of the total SBS-IF populati
VectivBio Appoints Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
07:15am, Tuesday, 25'th May 2021
Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of
CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering
09:53pm, Tuesday, 13'th Apr 2021
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by VectivBio Holding AG (Nasdaq: VECT), please note that in the first sentence o
VectivBio Announces Closing of $146.6 Million Initial Public Offering
08:06pm, Tuesday, 13'th Apr 2021
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, deve
US IPO Weekly Recap: The IPO Market Cools Off In A 2 IPO Week
02:17pm, Sunday, 11'th Apr 2021
Just two IPOs priced this past week, raising $222 million as the US IPO market continued to cool down. The IPO pipeline remained active, with 13 IPOs and 14 SPACs submitting initial filings this week.
Two Biotechs Are Set to Start Trading Today
11:34am, Friday, 09'th Apr 2021
VectivBio Holding and Reneo Pharmaceuticals are making their market debuts on Nasdaq.
